Im SA, Mukai H, Park IH, et al. - Researchers examined the benefit of palbociclib plus letrozole as initial treatment of estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer in Asians. They performed the random assignment of 666 eligible patients 2:1 to receive palbociclib plus letrozole or placebo plus letrozole. Of the participants, 95 were Asian. Consistent with the overall study population, Asian participants exhibited significantly improved progression-free survival (PFS) in correlation to the addition of palbociclib to letrozole. Relative to non-Asians, Asians experienced hematologic toxicities more frequently but these were manageable with early dose modifications while maintaining quality of life.